Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 505
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Harbeck, N. Search for Related Content PubMed Articles by Harbeck, N.

Abstract

Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue

Tech Univ of Munich, Munich, Germany; Univ Hosp Hamburg Eppendorf, Hamburg, Germany; Albany Medcl Coll, Albany, NY; Tech Univ of Dresden, Dresden, Germany; Charité, Berlin, Germany; Halitus Inst Médico, Buenos Aires, Argentina; Univ Hosp Regensburg, Regensburg, Germany; Institute of Oncology, Ljubljana, Slovenia; National Cancer Institute, Bari, Bari, Italy; Epigenomics AG, Berlin, Germany

505

Background: In hormone receptor positive, node-negative breast cancer, many patients receive chemo-endocrine therapy although endocrine therapy alone would have been sufficient in view of their excellent prognosis. In a microarray study, we recently reported that PITX2 methylation correlates strongly with the risk of recurrence after adjuvant tamoxifen. Here, we present results from a large multicenter study initiated to validate PITX2 methylation as an outcome predictor for adjuvant tamoxifen using paraffin-embedded tumor tissue. Methods: A real-time PCR assay was developed to test PITX2 methylation in paraffin-embedded tissue. Matched frozen and embedded samples (n=89) were analyzed to ensure comparability of Results: Then, we analyzed paraffin-embedded tumors of 422 node-negative patients from 9 clinical centers treated with tamoxifen alone; none of the patients had been included in the prior studies. Results: Results from the matched pairs indicated that the assay works well on paraffin-embedded material (correlation coefficient = 0.81). In the independent cohort, PITX2 methylation was strongly correlated with outcome (Cox proportional hazard model, p=0.025). In the group with low PITX2 methylation (45% of the cohort), 98% of the patients were metastasis-free after 10 years, compared to only 85% in the group with high PITX2 methylation. In a multivariate model, PITX2 methylation added significant information to conventional factors such as tumor size, grade, and age. Conclusions: This study validates PITX2 methylation as outcome predictor after adjuvant tamoxifen. Together with our previous studies, we have now analyzed over 750 patients, using two different Methods: In all studies, PITX2 methylation was consistently associated with poor outcome. Furthermore, we have now shown that PITX2 methylation can be reliably measured in paraffin-embedded tissue. The results provide substantial evidence that PITX2 DNA methylation is suitable for routine clinical use in order to predict outcome in node-negative, tamoxifen-treated patients, and to identify low-risk patients who can be spared the burden of additional cytotoxic therapy.

Abstract presentation from the 2005 ASCO Annual Meeting